Evidence map›Paper›PMID 40266069›Full record

ArticleVaccines2025

A Candidate Ac

Vladimir A Ledov, Victor V Romanenko, Marina E Golovina, Biana I Alkhazova, Alexander L Kovalchuk, Petr G Aparin

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vladimir A LedovATVD-Team Co, Ltd., 115522 Moscow, Russia.
Victor V RomanenkoATVD-Team Co, Ltd., 115522 Moscow, Russia.ORCID 0000-0002-9977-8845
Marina E GolovinaATVD-Team Co, Ltd., 115522 Moscow, Russia.
Biana I AlkhazovaATVD-Team Co, Ltd., 115522 Moscow, Russia.
Alexander L KovalchukATVD-Team Co, Ltd., 115522 Moscow, Russia.ORCID 0000-0003-2761-0442
Petr G AparinATVD-Team Co, Ltd., 115522 Moscow, Russia.

Funding

ATVD-Team Co, ltd, 24, Kashirskoe shosse, 115478 Moscow, Russia N/A
6 · The paper itself

Abstract

objectivesDetermination of reactogenicity and immunogenicity of a pentavalent candidate vaccine against

methodsThe study involved 80 healthy adult volunteers aged 18-55 years. Groups were subcutaneously immunized twice at a 30-day interval with 62.5 μg/0.5 mL or 125 μg/0.5 mL of the vaccine.

resultsDuring the entire 8-month period of post-vaccination observation, the vaccine was well tolerated, with no local or systemic reactions detected objectively. The results of laboratory studies demonstrated no effect on the main indicators of hemogram, biochemical blood test, or urinalysis. IgA, IgG, and IgM levels against LPS

conclusionsthe tolerability of PLVF and the pronounced humoral immune response allow us to proceed to the phase 3 clinical trial stage.

Indexed as

lipopolysaccharideShigella flexnerivaccine

Identifiers

PMID40266069
PMCPMC11945589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.